BeOne Medicines AG (NASDAQ: ONC) Stock Competitors & Peer Comparison
See ONC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ONC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ONC | $369.06 | -1.34% | 39.4B | 64.98 | $5.68 | N/A |
| VRTX | $499.74 | -1.77% | 126.7B | 26.26 | $19.03 | N/A |
| MRNA | $218.01 | -7.82% | 87B | -26.75 | -$8.15 | N/A |
| REGN | $790.74 | -0.70% | 81.4B | 17.33 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $819.14 | -3.21% | 51.5B | 29.53 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $177.96 | -5.97% | 38.1B | -20.18 | -$8.82 | N/A |
| RVMDW | $8.40 | -13.98% | 34.8B | -0.95 | -$8.82 | N/A |
| ALNY | $231.83 | -0.94% | 31B | 41.79 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ONC vs VRTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, VRTX has a market cap of 126.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while VRTX trades at $499.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas VRTX's P/E ratio is 26.26. In terms of profitability, ONC's ROE is +0.14%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ONC is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ONC vs MRNA Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MRNA has a market cap of 87B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MRNA trades at $218.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MRNA's P/E ratio is -26.75. In terms of profitability, ONC's ROE is +0.14%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ONC is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ONC vs REGN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, REGN has a market cap of 81.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while REGN trades at $790.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas REGN's P/E ratio is 17.33. In terms of profitability, ONC's ROE is +0.14%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ONC is similarly volatile compared to REGN. This indicates similar risk in terms of short-term price fluctuations for ONC.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ONC vs VRNA Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ONC's ROE is +0.14%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ONC is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ONC vs ARGX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ARGX has a market cap of 51.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ARGX trades at $819.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ARGX's P/E ratio is 29.53. In terms of profitability, ONC's ROE is +0.14%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ONC is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ONC vs SGEN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ONC's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ONC is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ONC vs RVMD Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RVMD has a market cap of 38.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RVMD trades at $177.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RVMD's P/E ratio is -20.18. In terms of profitability, ONC's ROE is +0.14%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ONC is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ONC vs RVMDW Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RVMDW has a market cap of 34.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RVMDW trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RVMDW's P/E ratio is -0.95. In terms of profitability, ONC's ROE is +0.14%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ONC is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ONC vs ALNY Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ALNY has a market cap of 31B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ALNY trades at $231.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ALNY's P/E ratio is 41.79. In terms of profitability, ONC's ROE is +0.14%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ONC is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ONC vs ROIV Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ROIV has a market cap of 24.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ROIV trades at $33.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ROIV's P/E ratio is -31.90. In terms of profitability, ONC's ROE is +0.14%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ONC is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ONC vs INCY Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while INCY trades at $113.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas INCY's P/E ratio is 15.20. In terms of profitability, ONC's ROE is +0.14%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ONC is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ONC.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ONC vs UTHR Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, UTHR has a market cap of 22.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while UTHR trades at $533.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas UTHR's P/E ratio is 19.07. In terms of profitability, ONC's ROE is +0.14%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ONC is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
ONC vs GMAB Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, GMAB has a market cap of 22.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while GMAB trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas GMAB's P/E ratio is 27.87. In terms of profitability, ONC's ROE is +0.14%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ONC is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ONC.Check GMAB's competition here
BioNTech SE (NASDAQ: BNTX)
ONC vs BNTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, BNTX has a market cap of 21.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while BNTX trades at $87.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas BNTX's P/E ratio is -11.37. In terms of profitability, ONC's ROE is +0.14%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
ONC vs INSM Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, INSM has a market cap of 21B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while INSM trades at $96.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas INSM's P/E ratio is -23.42. In terms of profitability, ONC's ROE is +0.14%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ONC is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ONC vs BGNE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ONC's ROE is +0.14%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ONC is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ONC vs DNA-WT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ONC's ROE is +0.14%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ONC is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ONC vs EXEL Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, EXEL has a market cap of 15.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while EXEL trades at $62.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas EXEL's P/E ratio is 17.78. In terms of profitability, ONC's ROE is +0.14%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ONC is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ONC.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ONC vs ASND Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ASND trades at $225.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ASND's P/E ratio is -93.07. In terms of profitability, ONC's ROE is +0.14%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ONC is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ASND's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ONC vs HALO Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, HALO has a market cap of 13.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while HALO trades at $121.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas HALO's P/E ratio is 22.73. In terms of profitability, ONC's ROE is +0.14%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ONC is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ONC.Check HALO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ONC vs NBIX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, NBIX has a market cap of 13.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while NBIX trades at $135.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas NBIX's P/E ratio is 19.61. In terms of profitability, ONC's ROE is +0.14%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ONC is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ONC vs JAZZ Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, JAZZ has a market cap of 13.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while JAZZ trades at $210.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas JAZZ's P/E ratio is 7.84. In terms of profitability, ONC's ROE is +0.14%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ONC is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ONC.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ONC vs BBIO Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while BBIO trades at $66.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas BBIO's P/E ratio is -17.75. In terms of profitability, ONC's ROE is +0.14%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ONC is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ONC vs KRTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ONC's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ONC is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check KRTX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ONC vs SMMT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while SMMT trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas SMMT's P/E ratio is -13.06. In terms of profitability, ONC's ROE is +0.14%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ONC is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SMMT's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ONC vs TECH Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TECH trades at $72.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TECH's P/E ratio is 37.41. In terms of profitability, ONC's ROE is +0.14%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ONC is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ONC vs RNAM Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ONC's ROE is +0.14%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ONC is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ONC vs BMRN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while BMRN trades at $54.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas BMRN's P/E ratio is 26.30. In terms of profitability, ONC's ROE is +0.14%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ONC is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ONC vs MDGL Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MDGL has a market cap of 10.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MDGL trades at $449.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MDGL's P/E ratio is -35.12. In terms of profitability, ONC's ROE is +0.14%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ONC is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MDGL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ONC vs PCVX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while PCVX trades at $63.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas PCVX's P/E ratio is -8.34. In terms of profitability, ONC's ROE is +0.14%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ONC is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ONC vs IBRX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, IBRX has a market cap of 9.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while IBRX trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas IBRX's P/E ratio is -9.46. In terms of profitability, ONC's ROE is +0.14%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ONC is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ONC vs RXDX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ONC's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ONC vs KRYS Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, KRYS has a market cap of 9.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while KRYS trades at $316.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas KRYS's P/E ratio is 39.67. In terms of profitability, ONC's ROE is +0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ONC is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KRYS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ONC vs NUVL Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ONC's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ONC is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ONC.Check NUVL's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ONC vs TXG Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TXG trades at $69.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TXG's P/E ratio is -118.41. In terms of profitability, ONC's ROE is +0.14%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TXG's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ONC vs CRNX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ONC's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ONC is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CRNX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ONC vs TWST Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TWST has a market cap of 8.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TWST trades at $132.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TWST's P/E ratio is -59.80. In terms of profitability, ONC's ROE is +0.14%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ONC is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TWST's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ONC vs IMGN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ONC's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ONC is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ONC vs CAI Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CAI has a market cap of 8.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CAI trades at $30.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CAI's P/E ratio is 85.87. In terms of profitability, ONC's ROE is +0.14%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ONC is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CAI's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ONC vs KYMR Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, KYMR has a market cap of 8.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while KYMR trades at $104.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas KYMR's P/E ratio is -32.73. In terms of profitability, ONC's ROE is +0.14%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ONC is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ONC vs CYTK Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CYTK trades at $61.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CYTK's P/E ratio is -8.58. In terms of profitability, ONC's ROE is +0.14%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ONC is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CYTK's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ONC vs APGE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas APGE's P/E ratio is -31.19. In terms of profitability, ONC's ROE is +0.14%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ONC is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ONC vs BPMC Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ONC's ROE is +0.14%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ONC.Check BPMC's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ONC vs PTGX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, PTGX has a market cap of 8.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while PTGX trades at $128.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas PTGX's P/E ratio is 125.00. In terms of profitability, ONC's ROE is +0.14%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ONC is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PTGX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ONC vs TGTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TGTX trades at $53.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TGTX's P/E ratio is 19.55. In terms of profitability, ONC's ROE is +0.14%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ONC is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TGTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ONC vs AXSM Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, AXSM has a market cap of 8.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while AXSM trades at $157.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas AXSM's P/E ratio is -41.01. In terms of profitability, ONC's ROE is +0.14%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ONC is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check AXSM's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ONC vs CERE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CERE's P/E ratio is -16.47. In terms of profitability, ONC's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ONC is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CERE's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ONC vs ARWR Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ARWR has a market cap of 7.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ARWR trades at $55.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ARWR's P/E ratio is -24.85. In terms of profitability, ONC's ROE is +0.14%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ONC is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ARWR's competition here
Metsera, Inc. (NASDAQ: MTSR)
ONC vs MTSR Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ONC's ROE is +0.14%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ONC is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MTSR's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ONC vs SYRE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while SYRE trades at $79.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas SYRE's P/E ratio is -40.97. In terms of profitability, ONC's ROE is +0.14%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ONC is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SYRE's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ONC vs IONS Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, IONS has a market cap of 7.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while IONS trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas IONS's P/E ratio is -13.13. In terms of profitability, ONC's ROE is +0.14%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ONC is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IONS's competition here
Merus N.V. (NASDAQ: MRUS)
ONC vs MRUS Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ONC's ROE is +0.14%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ONC is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MRUS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ONC vs PRAX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while PRAX trades at $241.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas PRAX's P/E ratio is -18.70. In terms of profitability, ONC's ROE is +0.14%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ONC is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PRAX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ONC vs ACLX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ONC's ROE is +0.14%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ONC is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ONC vs RETA Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RETA's P/E ratio is -66.29. In terms of profitability, ONC's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ONC is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RETA's competition here
Abivax S.A. (NASDAQ: ABVX)
ONC vs ABVX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ABVX trades at $88.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ABVX's P/E ratio is -14.44. In terms of profitability, ONC's ROE is +0.14%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ONC is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ABVX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ONC vs CNTA Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ONC's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ONC is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CNTA's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ONC vs IOVA Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, IOVA has a market cap of 6.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while IOVA trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas IOVA's P/E ratio is -18.66. In terms of profitability, ONC's ROE is +0.14%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ONC is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IOVA's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ONC vs TERN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TERN's P/E ratio is -51.41. In terms of profitability, ONC's ROE is +0.14%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ONC is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check TERN's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ONC vs RYTM Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RYTM trades at $86.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RYTM's P/E ratio is -27.71. In terms of profitability, ONC's ROE is +0.14%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ONC is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RYTM's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ONC vs LGND Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while LGND trades at $295.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas LGND's P/E ratio is 32.44. In terms of profitability, ONC's ROE is +0.14%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ONC is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ONC.Check LGND's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ONC vs BLTE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while BLTE trades at $142.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas BLTE's P/E ratio is -76.47. In terms of profitability, ONC's ROE is +0.14%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ONC is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check BLTE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ONC vs CDTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ONC's ROE is +0.14%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ONC is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ONC vs ABCM Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ONC's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ONC is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ABCM's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ONC vs IMVT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while IMVT trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas IMVT's P/E ratio is -9.48. In terms of profitability, ONC's ROE is +0.14%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ONC is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check IMVT's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ONC vs ISEE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ONC's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ONC is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ISEE's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ONC vs KOD Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, KOD has a market cap of 5.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while KOD trades at $85.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas KOD's P/E ratio is -20.56. In terms of profitability, ONC's ROE is +0.14%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ONC is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ONC.Check KOD's competition here
CG Oncology Inc. (NASDAQ: CGON)
ONC vs CGON Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CGON trades at $59.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CGON's P/E ratio is -22.25. In terms of profitability, ONC's ROE is +0.14%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ONC is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CGON's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ONC vs APLS Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas APLS's P/E ratio is 38.35. In terms of profitability, ONC's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ONC is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ONC.Check APLS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ONC vs MIRM Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MIRM trades at $80.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MIRM's P/E ratio is -5.51. In terms of profitability, ONC's ROE is +0.14%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ONC is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ONC vs COGT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while COGT trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas COGT's P/E ratio is -13.99. In terms of profitability, ONC's ROE is +0.14%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ONC is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ONC vs PTCT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, PTCT has a market cap of 4.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while PTCT trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas PTCT's P/E ratio is -25.42. In terms of profitability, ONC's ROE is +0.14%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ONC is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ONC vs SRRK Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while SRRK trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas SRRK's P/E ratio is -11.57. In terms of profitability, ONC's ROE is +0.14%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ONC is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ONC.Check SRRK's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ONC vs CRSP Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CRSP trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CRSP's P/E ratio is -10.35. In terms of profitability, ONC's ROE is +0.14%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ONC is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ONC.Check CRSP's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ONC vs ORKA Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ORKA has a market cap of 4.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ORKA trades at $71.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ORKA's P/E ratio is -37.08. In terms of profitability, ONC's ROE is +0.14%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ONC is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ORKA's competition here
Erasca, Inc. (NASDAQ: ERAS)
ONC vs ERAS Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ERAS trades at $13.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ERAS's P/E ratio is -14.40. In terms of profitability, ONC's ROE is +0.14%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ONC is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ONC vs TVTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TVTX's P/E ratio is -110.22. In terms of profitability, ONC's ROE is +0.14%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ONC is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ONC vs FOLD Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ONC's ROE is +0.14%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ONC is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ONC.Check FOLD's competition here
Veradermics, Incorporated (NYSE: MANE)
ONC vs MANE Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MANE trades at $108.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MANE's P/E ratio is -34.64. In terms of profitability, ONC's ROE is +0.14%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ONC is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ONC.Check MANE's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ONC vs AKRO Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ONC's ROE is +0.14%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ONC is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ONC.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ONC vs ALPN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ONC's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ONC is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ONC.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ONC vs DFTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, DFTX has a market cap of 4.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while DFTX trades at $32.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas DFTX's P/E ratio is N/A. In terms of profitability, ONC's ROE is +0.14%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ONC is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DFTX's competition here
Opthea Limited (NASDAQ: OPT)
ONC vs OPT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas OPT's P/E ratio is -1.52. In terms of profitability, ONC's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ONC is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ONC.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ONC vs PRTC Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ONC's ROE is +0.14%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ONC is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ONC.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ONC vs MRTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ONC's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ONC is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check MRTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ONC vs DNTH Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while DNTH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas DNTH's P/E ratio is -17.39. In terms of profitability, ONC's ROE is +0.14%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ONC is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ONC.Check DNTH's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ONC vs EWTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while EWTX trades at $37.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas EWTX's P/E ratio is -20.10. In terms of profitability, ONC's ROE is +0.14%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ONC is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check EWTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ONC vs CPRX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ONC's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ONC is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CPRX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ONC vs ADPT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ADPT has a market cap of 3.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ADPT trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ADPT's P/E ratio is -58.59. In terms of profitability, ONC's ROE is +0.14%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ONC is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ADPT's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ONC vs ABCL Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ABCL trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ABCL's P/E ratio is -21.85. In terms of profitability, ONC's ROE is +0.14%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ONC is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ONC vs RYZB Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ONC's ROE is +0.14%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ONC is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ONC.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ONC vs CBAY Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ONC's ROE is +0.14%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ONC is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ONC.Check CBAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ONC vs TNGX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TNGX trades at $22.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TNGX's P/E ratio is -26.55. In terms of profitability, ONC's ROE is +0.14%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ONC is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ONC vs TLX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while TLX trades at $10.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas TLX's P/E ratio is 111.59. In terms of profitability, ONC's ROE is +0.14%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ONC is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check TLX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
ONC vs ARQT Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, ARQT has a market cap of 3.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while ARQT trades at $28.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas ARQT's P/E ratio is 137.33. In terms of profitability, ONC's ROE is +0.14%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, ONC is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for ONC.Check ARQT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ONC vs RLAY Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, RLAY has a market cap of 3.6B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while RLAY trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas RLAY's P/E ratio is -10.37. In terms of profitability, ONC's ROE is +0.14%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ONC is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ONC.Check RLAY's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ONC vs SWTX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ONC's ROE is +0.14%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ONC is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ONC.Check SWTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ONC vs LEGN Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while LEGN trades at $18.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas LEGN's P/E ratio is -27.10. In terms of profitability, ONC's ROE is +0.14%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ONC is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ONC.Check LEGN's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ONC vs AMLX Comparison October 2026
BeOne Medicines AG (NASDAQ: ONC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONC stands at 39.4B. In comparison, AMLX has a market cap of 3.3B. Regarding current trading prices, ONC is priced at $369.06 on the NASDAQ, while AMLX trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONC currently has a P/E ratio of 64.98, whereas AMLX's P/E ratio is -17.56. In terms of profitability, ONC's ROE is +0.14%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, ONC is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ONC.Check AMLX's competition here